Cargando…
HER2 exon 20 insertion mutations and myelosuppression in lung adenocarcinoma patient: a case report and response to trastuzumab deruxtecan
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) mutations occur in 2% of lung cancers. CASE PRESENTATION: In this report, we presented a case of an Asian female who was diagnosed with lung adenocarcinoma. NGS results indicated HER2 exon 20 insertion mutation and PET/CT results showed mul...
Autores principales: | Wang, Bin, Song, Yang, Yang, Xin, Chen, Chuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071679/ https://www.ncbi.nlm.nih.gov/pubmed/37013547 http://dx.doi.org/10.1186/s13019-023-02181-w |
Ejemplares similares
-
Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato, Yuki, et al.
Publicado: (2021) -
HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
por: Zhang, Xinyong, et al.
Publicado: (2020) -
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022) -
Trastuzumab deruxtecan for the treatment of patients with
HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021) -
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)